CD8A and leukemia: HVEM endowed leukemia cells with a survival advantage and protected them from immune attack facilitating tumor dissemination and the formation of tumor metastases in the hematopoietic and the non-hematopoietic compartments despite the existence of natural barriers of resistance (NK cells and CD8 T cells) to tumor implantation in F1 recipients.